BioXcel Therapeutics (BTAI) Set to Announce Quarterly Earnings on Thursday

Posted by Scott Moore on Nov 9th, 2024

BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) will be announcing its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter.

BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.55. The firm had revenue of $1.10 million for the quarter, compared to the consensus estimate of $0.80 million. During the same quarter in the previous year, the business posted ($1.83) EPS. On average, analysts expect BioXcel Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioXcel Therapeutics Stock Up 1.5 %

BTAI opened at $0.68 on Friday. BioXcel Therapeutics has a twelve month low of $0.51 and a twelve month high of $5.62. The company has a fifty day moving average of $0.60 and a 200-day moving average of $1.14. The stock has a market cap of $27.70 million, a PE ratio of -0.19 and a beta of 0.29.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. HC Wainwright dropped their price objective on BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, October 21st. Canaccord Genuity Group reissued a “buy” rating and issued a $7.00 price target on shares of BioXcel Therapeutics in a research note on Friday, August 30th. Finally, UBS Group reduced their price objective on shares of BioXcel Therapeutics from $3.50 to $1.00 and set a “neutral” rating for the company in a research report on Friday, August 9th.

Check Out Our Latest Report on BTAI

BioXcel Therapeutics Company Profile

(Get Free Report)

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.